Unique ID issued by UMIN | UMIN000041817 |
---|---|
Receipt number | R000047744 |
Scientific Title | Concentration of vascular endothelial growth factor and medicine in serum and aqueous humor of patients with neovascular age-related macular degeneration before and after anti-VEGF therapy |
Date of disclosure of the study information | 2020/09/17 |
Last modified on | 2024/03/05 15:08:09 |
VEGF and medicine concentration in serum and eye of patients with age-related macular degeneration before and after anti-VEGF therapy
Serum and ocular VEGF and medicine concentration with age-related macular degeneration
Concentration of vascular endothelial growth factor and medicine in serum and aqueous humor of patients with neovascular age-related macular degeneration before and after anti-VEGF therapy
Serum and ocular VEGF and medicine concentration with age-related macular degeneration
Japan |
age-related macular degeneration
Ophthalmology |
Others
NO
To investigate the general and ocular effect of anti-vascular endothelial growth factor therapy by measuring of serum concentration of vascular endothelial growth factor of patients with age-related macular degeneration before and after the intravitreal injection of anti-vascular endothelial growth factor
Pharmacokinetics
Not applicable
The serum concentration of vascular endothelial growth factor before, 1 week and 1, 2, 3, 4, 5-month after the intravitreal injection of anti-vascular endothelial growth factor
The correlation of change in best corrected visual acuity or central retinal subfield thickness and serum concentration of vascular endothelial growth factor before, 1 week and 1, 2, 3, 4, 5- month after the injection of anti-vascular endothelial growth factor
Observational
50 | years-old | <= |
Not applicable |
Male and Female
Patient with neovascular age-related macular degeneration, male or female, people 50 years old or older with informed consent.
Patients are judged to be inappropriate by doctors in charge.
Patients who would like to withdraw their consent.
30
1st name | Tomoko |
Middle name | |
Last name | Sawada |
Shiga University of Medical Science
Department of Ophthalmology
520-2192
Seta Tsukinowa-cho, Otsu, Shiga, JAPAN
0775482276
tsawada@belle.shiga-med.ac.jp
1st name | Tomoko |
Middle name | |
Last name | Sawada |
Shiga University of Medical Science
Department of Ophthalmology
520-2192
Seta Tsukinowa-cho, Otsu, Shiga, JAPAN
0775482276
tsawada@belle.shiga-med.ac.jp
Department of Ophthalmology, Shiga University of Medical Science
Ministry of Education, Culture, Sports, Science and Technology
Japanese Governmental office
Research Ethics Committee of Shiga University of Medical Science
Seta Tsukinowa-cho, Otsu, Shiga, JAPAN
077-548-3576
hqrec@belle.shiga-med.ac.jp
NO
滋賀医科大学医学部附属病院(滋賀県)
2020 | Year | 09 | Month | 17 | Day |
Unpublished
Completed
2020 | Year | 07 | Month | 09 | Day |
2020 | Year | 07 | Month | 09 | Day |
2020 | Year | 09 | Month | 17 | Day |
2023 | Year | 03 | Month | 31 | Day |
Patients who visit our hospital and indicate to receive anti-VEGF therapy and start their initial intravitreal injection of anti-VEGF in March 3rd, 2022.
Outcomes;
Background factors: year of birth, gender, life history (smoking history)
Treatment: Type of anti-VEGF drug, number of injection
Ophthalmological observations: visual acuity, intraocular pressure, slit lamp microscopy, ophthalmoscope
Images: funds angiography, central retinal thickness by optical coherence tomography (OCT), OCT-angiography
Aqueous VEGF concentration, serum VEGF concentration
2020 | Year | 09 | Month | 17 | Day |
2024 | Year | 03 | Month | 05 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047744